Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort A efficacy, safety, and biomarker results.

EY Yu; JMMP Rodriguez; G Gravis; B Laguerre; JAA Arija; S Oudard; PCC Fong; MP Kolinsky; Marinela Augustin; T Todenhofer; AE Kam; H Gurney; A Tafreshi; M Retz; WR Berry; N Mar; HY Wu; P Qiu; C Schloss; JS De Bono

Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort A efficacy, safety, and biomarker results.

EY Yu, JMMP Rodriguez, G Gravis, B Laguerre, JAA Arija, S Oudard, PCC Fong, MP Kolinsky, Marinela Augustin, T Todenhofer, AE Kam, H Gurney, A Tafreshi, M Retz, WR Berry, N Mar, HY Wu, P Qiu, C Schloss, JS De Bono

Department of Internal Medicine V, Division of Oncology and Hematology

Research output: Contribution to journal › published Abstract (Journal) › peer-review

8 Citations (Web of Science)

Original language	English
Journal	JOURNAL OF CLINICAL ONCOLOGY
Volume	38
Issue number	15
Publication status	Published - 2020

Cite this

Yu, EY., Rodriguez, JMMP., Gravis, G., Laguerre, B., Arija, JAA., Oudard, S., Fong, PCC., Kolinsky, MP., Augustin, M., Todenhofer, T., Kam, AE., Gurney, H., Tafreshi, A., Retz, M., Berry, WR., Mar, N., Wu, HY., Qiu, P., Schloss, C., & De Bono, JS. (2020). Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort A efficacy, safety, and biomarker results. JOURNAL OF CLINICAL ONCOLOGY , 38(15).

Yu, EY ; Rodriguez, JMMP ; Gravis, G et al. / Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort A efficacy, safety, and biomarker results. In: JOURNAL OF CLINICAL ONCOLOGY 2020 ; Vol. 38, No. 15.

@article{758d146c5cbc45f79b3249a7a00d8e6a,

title = "Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort A efficacy, safety, and biomarker results.",

author = "EY Yu and JMMP Rodriguez and G Gravis and B Laguerre and JAA Arija and S Oudard and PCC Fong and MP Kolinsky and Marinela Augustin and T Todenhofer and AE Kam and H Gurney and A Tafreshi and M Retz and WR Berry and N Mar and HY Wu and P Qiu and C Schloss and {De Bono}, JS",

year = "2020",

language = "English",

volume = "38",

journal = "JOURNAL OF CLINICAL ONCOLOGY ",

issn = "0732-183X",

publisher = "Lippincott Williams & Wilkins ",

number = "15",

}

Yu, EY, Rodriguez, JMMP, Gravis, G, Laguerre, B, Arija, JAA, Oudard, S, Fong, PCC, Kolinsky, MP, Augustin, M, Todenhofer, T, Kam, AE, Gurney, H, Tafreshi, A, Retz, M, Berry, WR, Mar, N, Wu, HY, Qiu, P, Schloss, C & De Bono, JS 2020, 'Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort A efficacy, safety, and biomarker results.', JOURNAL OF CLINICAL ONCOLOGY , vol. 38, no. 15.

Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort A efficacy, safety, and biomarker results. / Yu, EY; Rodriguez, JMMP; Gravis, G et al.
In: JOURNAL OF CLINICAL ONCOLOGY , Vol. 38, No. 15, 2020.

Research output: Contribution to journal › published Abstract (Journal) › peer-review

TY - JOUR

T1 - Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort A efficacy, safety, and biomarker results.

AU - Yu, EY

AU - Rodriguez, JMMP

AU - Gravis, G

AU - Laguerre, B

AU - Arija, JAA

AU - Oudard, S

AU - Fong, PCC

AU - Kolinsky, MP

AU - Augustin, Marinela

AU - Todenhofer, T

AU - Kam, AE

AU - Gurney, H

AU - Tafreshi, A

AU - Retz, M

AU - Berry, WR

AU - Mar, N

AU - Wu, HY

AU - Qiu, P

AU - Schloss, C

AU - De Bono, JS

PY - 2020

Y1 - 2020

M3 - published Abstract (Journal)

SN - 0732-183X

VL - 38

JO - JOURNAL OF CLINICAL ONCOLOGY

JF - JOURNAL OF CLINICAL ONCOLOGY

IS - 15

ER -

Yu EY, Rodriguez JMMP, Gravis G, Laguerre B, Arija JAA, Oudard S et al. Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort A efficacy, safety, and biomarker results. JOURNAL OF CLINICAL ONCOLOGY . 2020;38(15).